MET and non-small cell lung carcinoma: Single cases of EGFRm+ NSCLC with acquired MET amplification detected by liquid biopsy of plasma cfDNA and treated with combined Osimertinib–Crizotinib have been reported with a PFS between three and four months [30,54].